<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110525/" ref="ordinalpos=238&amp;ncbi_uid=6474943&amp;link_uid=PMC4110525" image-link="/pmc/articles/PMC4110525/figure/F4/" class="imagepopup">Figure 4.  From: Targeting Notch1 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family. </a></div><br /><div class="p4l_captionBody"><b>Inhibition of Notch1 signaling pathway decreased the sensitivity of MG63 and Saos-2 to cisplatin.</b> Real-time PCR indicated that HES1 mRNA in MG63 and Saos-2 had significantly less expression after DAPT treatment <b>(A and B)</b>. The sensitivity of MG63 and Saos-2 to cisplatin has significantly decreased after the inhibition of Notch1 signaling pathway <b>(C and D)</b>. (*P &lt; 0.05; **P &lt; 0.01).</div></div>